211 related articles for article (PubMed ID: 7679826)
1. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):635-7. PubMed ID: 7679826
[No Abstract] [Full Text] [Related]
2. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
3. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):679-88. PubMed ID: 7679840
[TBL] [Abstract][Full Text] [Related]
4. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
[No Abstract] [Full Text] [Related]
5. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
[No Abstract] [Full Text] [Related]
6. FK 506 used as rescue therapy for refractory liver allograft rejection.
Chen CL; Eng HL; Chen YS; Kuo YC; Sun CK
Transplant Proc; 1994 Aug; 26(4):1927-9. PubMed ID: 7520612
[No Abstract] [Full Text] [Related]
7. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach.
Woodle ES; Perdrizet GA; So SK; White HM; Marsh JW
Clin Transplant; 1995 Feb; 9(1):45-52. PubMed ID: 7537988
[TBL] [Abstract][Full Text] [Related]
8. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
9. FK 506 rescue therapy: early conversion improves efficacy.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1990-1. PubMed ID: 7682359
[No Abstract] [Full Text] [Related]
10. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
11. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.
Porayko MK; Gonwa TA; Klintmalm GB; Wiesner RH
Transplant Proc; 1995 Feb; 27(1):1114-6. PubMed ID: 7533358
[No Abstract] [Full Text] [Related]
12. [Rejection of a liver allograft. Diagnosis and treatment].
Calmus Y
Ann Radiol (Paris); 1994; 37(5):377-82. PubMed ID: 7527621
[TBL] [Abstract][Full Text] [Related]
13. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
[No Abstract] [Full Text] [Related]
14. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
[No Abstract] [Full Text] [Related]
15. OKT3 prophylaxis in liver transplant patients: a European and Australian multicenter, prospective controlled trial.
Höckerstedt K; Ericzon BG; Bismuth H; Chapuis Y; Farges O; Faure JL; Galmarini D; Houssin D; Lynch SV; Miguet J
Transplant Proc; 1993 Feb; 25(1 Pt 1):556-7. PubMed ID: 8438412
[No Abstract] [Full Text] [Related]
16. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
Mueller AR; Platz KP; Bechstein WO; Blumhardt G; Lobeck H; Hop U; Neuhaus P
Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
[No Abstract] [Full Text] [Related]
17. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection.
Lewis WD; Jenkins RL; Burke PA; Winn KM; Shaffer D; Lopez R; Monaco AP
Transplant Proc; 1991 Dec; 23(6):2989-91. PubMed ID: 1721336
[No Abstract] [Full Text] [Related]
18. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
Wiesner RH; Porayko MK; Wahlstrom HE; Gores GJ; Kamath PS; Hay JE; Krom RA
Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
[No Abstract] [Full Text] [Related]
19. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
20. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
[Next] [New Search]
